Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis

BACKGROUND: Urothelial carcinoma ranks the ninth among malignant cancers. We conducted this study to identify which patients could benefit more from the treatment of programmed death-1 (PD–1)/programmed death-ligand1 (PD–L1) inhibitors. MATERIALS AND METHODS: We performed literature searches, combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Junqi, Zhang, Chuanfeng, Hu, Jiegang, Tian, Qing, Wang, Xin, Gu, Hao, Zhang, Song, Zhao, Di, Fan, Ruitai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844756/
https://www.ncbi.nlm.nih.gov/pubmed/29552320
http://dx.doi.org/10.18632/oncotarget.24249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844756/
https://www.ncbi.nlm.nih.gov/pubmed/29552320
http://dx.doi.org/10.18632/oncotarget.24249

Ejemplares similares